Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cancer risk among sulfonylurea-treated patients with type 2 diabetes
NL-OMON26303Recruiting
- Sponsor
- Isala
- Start
- Jan 2017
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of gliclazide, glimepiride, tolbutamide and glibenclamide in type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by Isala. Primary endpoint: Within-sulfonylurea-class differences in obesity-related cancer risk. Started Jan 2017; status: recruiting.
02
Drugs
gliclazideglimepiridetolbutamideglibenclamide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON26303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26303.